Independent validation of a model using cell line chemosensitivity to predict response to therapy

Journal of the National Cancer Institute

Volumn 105, Issue 17, 2013, Pages 1284-1291

  Wang, Wenting ^b   Baggerly, Keith A ^b   Knudsen, Steen ^b   Askaa, Jon ^b   Mazin, Wiktor ^b   Coombes, Kevin R ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; MERCAPTOPURINE; METHOTREXATE; VINBLASTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CASE STUDY; CHEMOSENSITIVITY; CHILD; CLINICAL FEATURE; CLINICAL OBSERVATION; DISEASE FREE SURVIVAL; DRUG DOSE REGIMEN; DRUG MEGADOSE; FEMALE; GENE EXPRESSION; GENETIC DATABASE; HODGKIN DISEASE; HUMAN; MALE; MICROARRAY ANALYSIS; MONOTHERAPY; NUCLEOTIDE SEQUENCE; PREDICTIVE VALUE; PRESCHOOL CHILD; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SCHOOL CHILD; SCORING SYSTEM; STUDY; TREATMENT RESPONSE; VALIDATION STUDY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; BLEOMYCIN; BREAST NEOPLASMS; CELL LINE, TUMOR; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HODGKIN DISEASE; HUMANS; LINEAR MODELS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREDICTIVE VALUE OF TESTS; ROC CURVE; TREATMENT OUTCOME; VINBLASTINE;

EID: 84884475470     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djt202     Document Type: Article

References (26)

1. Augustine CK, Yoo JS, Potti A, et al. Genomic and molecular profiling predicts response to temozolomide in melanoma. Clin Cancer Res. 2009;15(2):502-510.
2. Bonnefoi H, Potti A, Delorenzi M, et al. Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol. 2007;8(12):1071-1078.
3. Hsu DS, Balakumaran BS, Acharya CR, et al. Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer. J Clin Oncol. 2007;25(28):4350-4357.
4. Potti A, Dressman HK, Bild A, et al. Genomic signatures to guide the use of chemotherapeutics. Nat Med. 2006;12(11):1294-1300.
5. Baggerly KA, Coombes KR. Deriving chemosensitivity from cell lines: forensic bioinformatics and reproducible research in high-throughput biology. Ann Appl Stat. 2009;3(4):1309-1334.
6. Coombes KR, Wang J, Baggerly KA. Microarrays: retracing steps. Nat Med. 2007;13(11):1276-1277; author reply 1277-1278.
7. Chen JJ, Knudsen S, Mazin W, Dahlgaard J, Zhang B. A 71-gene signature of TRAIL sensitivity in cancer cells. Mol Cancer Ther. 2012;11(1):34-44.
8. Institute of Medicine. Evolution of Translational Omics: Lessons Learned and the Path Forward. Washington, DC: National Academies Press; 2012.
9. Steidl C, Lee T, Shah SP, et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med. 11 2010;362(10):875-885.
10. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics. 2007;8(1):118-127.
11. Gerds TA, Cai T, Schumacher M. The performance of risk prediction models. Biom J. 2008;50(4):457-479.
12. Steyerberg EW, Vickers AJ, Cook NR, et al. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology. 2010;21(1):128-138.
13. Pencina MJ, D'Agostino RB, Sr., D'Agostino RB, Jr., Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27(2):157-172; discussion 207-212.
14. Pepe MS. The Statistical Evaluation of Medical Tests for Classification and Prediction. Oxford: Oxford University Press; 2003.
15. Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation. 2007;115(7):928-935.
16. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med. 1998;339(21):1506-1514.
17. Hollander M, Wolfe DA. Nonparametric Statistical Methods. New York: John Wiley & Sons; 1973:185-194 (Kendall and Spearman tests).
18. Sorich MJ, Pottier N, Pei D, et al. In vivo response to methotrexate forecasts outcome of acute lymphoblastic leukemia and has a distinct gene expression profile. PLoS Med. 2008;5(4):e83.
19. Juul N, Szallasi Z, Eklund AC, et al. Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials. Lancet Oncol. 2010;11(4):358-365.
20. Li Y, Zou L, Li Q, et al. Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Nat Med. 2010;16(2):214-218.
21. Dervieux T, Brenner TL, Hon YY, et al. De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo. Blood. 2002;100(4):1240-1247.
22. Rouzier R, Pusztai L, Delaloge S, et al. Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. J Clin Oncol. 2005;23(33):8331-8339.
23. Barretina J, Caponigro G, Stransky N, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483(7391):603-607.
24. Baggerly K. Disclose all data in publications. Nature. 2010;467(7314):401.
25. Baggerly KA, Coombes KR. What information should be required to support clinical omics publications? Clin Chem. 2011;57(5):688-690.
26. Brazma A, Hingamp P, Quackenbush J, et al. Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat Genet. 2001;29(4):365-371.